Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04305158
Other study ID # 239435
Secondary ID
Status Completed
Phase Early Phase 1
First received
Last updated
Start date March 28, 2022
Est. completion date August 10, 2023

Study information

Verified date April 2024
Source University of Arkansas
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Colon cancer is the second most common cancer in men and the third most common cancer in women worldwide. The clinical objectives of administering sedation for GI endoscopy are to relieve patient anxiety and discomfort and to improve the outcome of the examination. Use of N2O could potentially provide an alternate safe and cheap option for patients who do not prefer IV sedation for colonoscopy


Description:

Patients who are considered low risk for anesthesia administration (ASA class


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date August 10, 2023
Est. primary completion date August 10, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Men and women, more than 18 years old Scheduled for a colonoscopy at the Endoscopy unit Exclusion Criteria: - High ASA risk (IV/ >) - History of chronic pain - Allergy to N2O or opioid or BDZ - No consent - Recent head injury with impairment of consciousness or Intracranial / Middle Ear surgery within the previous 6 months with or without residual deficits. - Pneumothorax, air embolism - Decompression sickness or within 48 hours of an underwater dive - Severe emphysema with bullae - Gross abdominal distension with suspicion for bowel obstruction - Intoxication - Maxillofacial injuries (where patient unable to administer the drug using a mouthpiece/mask, or there is the risk of causing further damage to facial wounds and there may also be a significant risk of blood inhalation) - Patients with chronic pulmonary disease for whom an inspired oxygen concentration of more than 28% oxygen might be dangerous - Patients on Methotrexate - Where patients need assistance to hold the mask or mouthpiece. - Retinal surgery within the last three months - Any patient who does not otherwise clinically qualify for standard sedation methods (i.e., those who require general anesthesia)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nitrous Oxide
Patient receiving nitrous oxide are evaluated for success of the procedure

Locations

Country Name City State
United States University of Arkansas for Medical Sciences Little Rock Arkansas

Sponsors (1)

Lead Sponsor Collaborator
University of Arkansas

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cecal intubation rates and time of the procedure - total time and recovery Time required to complete the procedure and reach end of the colon 1 to 30 minutes
See also
  Status Clinical Trial Phase
Completed NCT04884893 - Effect of Nitrous Oxide on EEG Phase 1
Withdrawn NCT01622335 - Effect OF Nitrous Oxide On Acute Pain and Opioid Consumption, and Chronic Pain After Hysterectomy N/A
Completed NCT04301024 - Nitrous Oxyde Misuse Among Teenagers Consulting in an Addictology Center Dedicated to Young Drug Users in Montpellier
Not yet recruiting NCT04305990 - Demand-Driven Method for Gas Delivery in a Dental Setting N/A
Not yet recruiting NCT06430489 - Treatment of Suicidal Ideation in the Emergency Department Using Nitrous Oxide Phase 2
Completed NCT00482456 - Homocysteine After Nitrous Oxide Anesthesia Phase 4
Not yet recruiting NCT05579288 - Use of Nitrous Oxide for Pain Alleviation in Women Undergoing Osmotic Dilator Insertion for Dilatation and Evacuation Early Phase 1
Completed NCT05435118 - Use of the Equimolar Mixture of Oxide Nitrous and Oxygen (EMONO) Associated With Audiovisuals in Children N/A